|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:accessories
|
limited supply in early 2021
|
|
gptkbp:approves
|
gptkb:FDA
February 27, 2021
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:clinical_trial
|
over 40,000
multiple countries
Phase 3
|
|
gptkbp:clinical_trial_results_published_in
|
gptkb:The_New_England_Journal_of_Medicine
|
|
gptkbp:developed_by
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:dosage_form
|
gptkb:1
yes
|
|
gptkbp:emergency_services
|
yes
|
|
gptkbp:first_dose_effectiveness
|
72% in the US
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Janssen COVID-19 Vaccine
|
|
gptkbp:is_effective_against
|
approximately 66%
|
|
gptkbp:is_vulnerable_to
|
varies by region
global
international regulatory bodies
less than a year
single dose
logistical challenges in distribution
multiple academic institutions
mixed public perception
U. S. government funding
adenoviral vector
monovalent
significant in reducing COVID-19 cases
Ad26. COV2. S
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:marketed_as
|
Johnson & Johnson COVID-19 Vaccine
|
|
gptkbp:route_of_administration
|
intramuscular
|
|
gptkbp:safety_measures
|
VAERS
|
|
gptkbp:second_dose_effectiveness
|
not applicable
|
|
gptkbp:side_effect
|
thrombosis with thrombocytopenia syndrome
|
|
gptkbp:target_audience
|
adults 18 years and older
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:type
|
viral vector vaccine
|
|
gptkbp:vaccine_adverse_event_reporting
|
mandatory reporting
|
|
gptkbp:vaccine_approval_status
|
authorized for emergency use
|
|
gptkbp:vaccine_clinical_trial_phases
|
Phase 1, Phase 2, Phase 3
|
|
gptkbp:vaccine_clinical_trial_results
|
published in peer-reviewed journals
|
|
gptkbp:vaccine_effectiveness_against_death
|
high effectiveness
|
|
gptkbp:vaccine_effectiveness_against_hospitalization
|
high effectiveness
|
|
gptkbp:vaccine_effectiveness_against_variants
|
reduced effectiveness against some variants
|
|
gptkbp:vaccine_efficacy_against_hospitalization
|
100%
|
|
gptkbp:vaccine_efficacy_against_severe_disease
|
85%
|
|
gptkbp:vaccine_efficacy_duration
|
at least 8 months
|
|
gptkbp:vaccine_emergency_use_expiration
|
subject to review
|
|
gptkbp:vaccine_global_distribution
|
distributed through COVAX initiative
|
|
gptkbp:vaccine_impact_on_transmission
|
may reduce transmission
|
|
gptkbp:vaccine_informed_consent
|
required before administration
|
|
gptkbp:vaccine_monitoring_adverse_events
|
ongoing monitoring
|
|
gptkbp:vaccine_post_marketing_surveillance
|
ongoing surveillance
|
|
gptkbp:vaccine_public_health_guidelines
|
follow CDC guidelines
|
|
gptkbp:vaccine_public_health_recommendations
|
recommended for high-risk populations
|
|
gptkbp:vaccine_storage_requirements
|
standard refrigeration
|
|
gptkbp:whoemergency_use_listing
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:bfsLayer
|
4
|